Healthcare resource utilization and costs associated with non-adherence to imatinib treatment in chronic myeloid leukemia patients
The DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Patients with chronic myeloid leukemia (CML) who do not adhere to treatment may experience suboptimal outcomes. OBJECTIVE: To examine the association between adherence with imatinib and direct healthcare costs and resource utilization in a large group of privately insured CML patients. PATIENTS AND METHODS: CML patients under age 65 were identified with ICD-9 code 205.1X using MarketScan Commercial Claims data between 1/1/02 and 7/31/08. Patients were required to be continuously enrolled in a private insurance plan during the baseline and study periods, defined respectively as the 4 months prior to and the 12 months following imatinib initiation. Non-adherence was evaluated by the medication possession ratio (MPR), defined as the fraction of days during the study period that patients had filled prescriptions for imatinib, and stratified into two groups (low MPR: <85%, high MPR: > or =85%). Costs, inpatient admissions, and hospital days were compared between high and low adherence groups using Wilcoxon tests. Regression models compared utilization and costs controlling for age, sex, CML severity, Charlson comorbidity index, baseline costs, and other factors. RESULTS: The study sample consisted of 592 patients, where 242 (40.9%) patients were classified with a low MPR, while 350 (59.1%) had a high MPR. Mean MPR was 79% (95% confidence interval 76-81%). Patients with a low MPR incurred more all-cause inpatient visits (4.1 vs. 0.4; p < 0.001) and all-cause inpatient days (14.8 vs. 1.8; p < 0.001). Regression models demonstrated a 283% increase (US$56 324; p < 0.001) in non-imatinib costs within the low- vs. high-MPR group. The generalizability of this study is limited by the use of a privately insured population under 65 years of age as well as by the limitations common to claims data analyses. CONCLUSIONS: Imatinib adherence is an important issue for patients and physicians. Better imatinib adherence was associated with significantly lower resource utilization and costs in CML patients, as lower imatinib costs in low MPR patients were more than offset by higher non-imatinib costs mostly driven by inpatient services.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“One study reported total annual costs of $119 416,74 while the other gave a subgroup analysis based on classified adherence levels.33”
From Economic impact of medication non-adherence by disease groups: a systematic review (2018) · cites this paper as [74]
Experimental — accuracy not yet measured
Citations
Cites
Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases
DEYO, R. (1992) · Journal of Clinical Epidemiology · doi:10.1016/0895-4356(92)90133-8 · Cited by 10,452
Osterberg, L., & Blaschke, T. (2005) · New England Journal of Medicine · doi:10.1056/nejmra050100 · Cited by 7,974
Druker, B. J., Talpaz, M., Resta, D. J., Peng, B., Buchdunger, E., Ford, J. M., Lydon, N. B., Kantarjian, H., Capdeville, R., Ohno-Jones, S., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200104053441401 · Cited by 5,243
ROWLEY, J. D. (1973) · Nature · doi:10.1038/243290a0 · Cited by 4,291
Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells
Druker, B. J., Tamura, S., Buchdunger, E., Ohno, S., Segal, G. M., Fanning, S., Zimmermann, J., & Lydon, N. B. (1996) · Nature Medicine · doi:10.1038/nm0596-561 · Cited by 2,967
Hematologic and Cytogenetic Responses to Imatinib Mesylate in Chronic Myelogenous Leukemia
Kantarjian, H., Sawyers, C., Hochhaus, A., Guilhot, F., Schiffer, C., Gambacorti-Passerini, C., Niederwieser, D., Resta, D., Capdeville, R., Zoellner, U., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa011573 · Cited by 2,019
A small molecule–kinase interaction map for clinical kinase inhibitors
Fabian, M. A., Biggs, W. H., Treiber, D. K., Atteridge, C. E., Azimioara, M. D., Benedetti, M. G., Carter, T. A., Ciceri, P., Edeen, P. T., Floyd, M., et al. (2005) · Nature Biotechnology · doi:10.1038/nbt1068 · Cited by 1,892
Estimating log models: to transform or not to transform?
Manning, W. G., & Mullahy, J. (2001) · Journal of Health Economics · doi:10.1016/s0167-6296(01)00086-8 · Cited by 1,790
Impact of Medication Adherence on Hospitalization Risk and Healthcare Cost
Sokol, M. C., McGuigan, K. A., Verbrugge, R. R., & Epstein, R. S. (2005) · Medical Care · doi:10.1097/01.mlr.0000163641.86870.af · Cited by 1,729
Sociobehavioral Determinants of Compliance with Health and Medical Care Recommendations
Becker, M. H., & Maiman, L. A. (1975) · Medical Care · doi:10.1097/00005650-197501000-00002 · Cited by 1,582
Research works printed but not linked: 6
- Nowell PC, 1960, J Natl Cancer Inst, 25, 85
- Lee WC, 2006, Manag Care Interface, 19, 31
- Doti C, 2007, Blood (ASH Annual Meeting Abstracts), 110, Abstract 4553
- Cervantes F, 2003, Haematologica, 88, 1117
- Sikka R, 2005, Am J Manag Care, 11, 449
- Greenberg RN., 1984, Clin Ther, 6, 592
Cited by
Economic impact of medication non-adherence by disease groups: a systematic review
Cutler, R. L., Fernandez-Llimos, F., Frommer, M., Benrimoj, C., & Garcia-Cardenas, V. (2018) · BMJ Open · doi:10.1136/bmjopen-2017-016982 · Cited by 900
Cost Sharing and Adherence to Tyrosine Kinase Inhibitors for Patients With Chronic Myeloid Leukemia
Dusetzina, S. B., Winn, A. N., Abel, G. A., Huskamp, H. A., & Keating, N. L. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.52.9123 · Cited by 500
Autophagy as a molecular target for cancer treatment
Kocaturk, N. M., Akkoc, Y., Kig, C., Bayraktar, O., Gozuacik, D., & Kutlu, O. (2019) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2019.04.011 · Cited by 387
A Systematic Review of Adherence to Oral Antineoplastic Therapies
Greer, J. A., Amoyal, N., Nisotel, L., Fishbein, J. N., MacDonald, J., Stagl, J., Lennes, I., Temel, J. S., Safren, S. A., & Pirl, W. F. (2016) · The Oncologist · doi:10.1634/theoncologist.2015-0405 · Cited by 344
Treatment Satisfaction and Adherence to Oral Chemotherapy in Patients With Cancer
Jacobs, J. M., Pensak, N. A., Sporn, N. J., MacDonald, J. J., Lennes, I. T., Safren, S. A., Pirl, W. F., Temel, J. S., & Greer, J. A. (2017) · Journal of Oncology Practice · doi:10.1200/jop.2016.019729 · Cited by 162
Metadata
- Authors
- Wu, E. Q., Johnson, S., Beaulieu, N., Arana, M., Bollu, V., Guo, A., Coombs, J., Feng, W., & Cortes, J.
- Affiliations
- Analysis Group (United States) (US)
- Novartis (United States) (US)
- MD Anderson Cancer Center, Houston, TX
- Corresponding author
- Wu, Eric Q.
- Venue
- Current Medical Research and Opinion
- Publisher
- Informa UK Limited
- Published
- 2009-11-11
- Volume
- 26
- Issue
- 1
- Pages
- 61-69
- ISSN
- 0300-7995 (ISSN-L)
- 1473-4877
- OpenAlex
- W1982993780
- Semantic Scholar
- 38ce2ef48c4e01e9ac8bab4ad561e4e31b9a41e9
- Cited by
- 126
- References
- 48
- Citations by year
- 2026: 4 · 2025: 1 · 2024: 6 · 2023: 3 · 2022: 7 · 2021: 5 · 2020: 5 · 2019: 10 · 2018: 3 · 2017: 16 · 2016: 4 · 2015: 10 · 2014: 14 · 2013: 15 · 2012: 13
- FWCI
- 5.56
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Current Medical Research and Opinion (publishedVersion)
- PubMed (publishedVersion)
- Funders
- University of California, San Francisco
- Topics
- Health Sciences › Medicine › Family Practice › Medication Adherence and Compliance
- Health Sciences › Medicine › Hematology › Chronic Myeloid Leukemia Treatments
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Economic and Financial Impacts of Cancer
- Keywords
- chronic myeloid leukemia, imatinib, medication adherence, medication possession ratio, health care costs, healthcare resource utilization, hospitalization, length of hospital stay, privately insured patients, generalizability of findings, comorbidities
- MeSH terms
- Imatinib Mesylate, Antineoplastic Agents, Benzamides, Humans, Patient Compliance, Piperazines, Pyrimidines, Health Care Rationing, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Health Care Costs
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Healthcare resource utilization and costs associated with non-adherence to imatinib treatment in chronic myeloid leukemia patients. https://app.cochat.ai/papers/10.1185/03007990903396469
- The paper
- Wu, E. Q., Johnson, S., Beaulieu, N., Arana, M., Bollu, V., Guo, A., Coombs, J., Feng, W., & Cortes, J. (2010). Healthcare resource utilization and costs associated with non-adherence to imatinib treatment in chronic myeloid leukemia patients. Current Medical Research and Opinion. https://doi.org/10.1185/03007990903396469
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.